

Idiopathic CD4+ Lymphocytopenia - Pipeline Insight, 2019

<https://marketpublishers.com/r/IABE7B897EEEN.html>

Date: August 2019

Pages: 60

Price: US\$ 1,250.00 (Single User License)

ID: IABE7B897EEEN

Abstracts

This report can be delivered to the clients within 24 Hours

"Idiopathic CD4+ Lymphocytopenia - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Idiopathic CD4+ Lymphocytopenia pipeline landscape is provided which includes the disease overview and Idiopathic CD4+ Lymphocytopenia treatment guidelines. The assessment part of the report embraces, in depth Idiopathic CD4+ Lymphocytopenia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Idiopathic CD4+ Lymphocytopenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Idiopathic CD4+ Lymphocytopenia Understanding

According to the US Centers for Disease Control and Prevention (CDC), Idiopathic CD4 lymphocytopenia (ICL) is a rare primary immunodeficiency disorder characterized by persistent CD4 T-cell lymphopenia (less than 300 cells/ μ L on multiple occasions or of less than 20% of total T cells on more than one occasion) with no evidence of human immunodeficiency virus (HIV) infection or no association with any other underlying primary or secondary immune deficiency or therapy associated with depressed levels of CD4 T cells. The clinical presentation can range from serious opportunistic infections to incidentally diagnosed asymptomatic individuals. Patients typically present opportunistic infections with cryptococcal, mycobacterial, candidal, varicella zoster virus infections and without the evidence of HIV infection. Progressive multifocal leukoencephalopathy,

malignancies mainly lymphoproliferative disorders, or autoimmune disorders are commonly associated with lymphocytopenia. ICL is a condition of unknown etiology and is considered a heterogeneous syndrome possibly encompassing different disorders sharing the common feature of reduced circulating CD4 T-cell counts. Most of the knowledge about ICL comes from scattered case reports due to rarity of this condition and patients with ICL appear to be epidemiologically, clinically, and immunologically heterogeneous.

Idiopathic CD4+ Lymphocytopenia Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Idiopathic CD4+ Lymphocytopenia targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Idiopathic CD4+ Lymphocytopenia pipeline report covers 3+ companies. Some of the key players include NeImmuneTech (Hyleukin-7) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Idiopathic CD4+ Lymphocytopenia Analytical Perspective by DelveInsight

In-depth Idiopathic CD4+ Lymphocytopenia Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

Idiopathic CD4+ Lymphocytopenia Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development

stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report

The Idiopathic CD4+ Lymphocytopenia report provides an overview of therapeutic pipeline activity for Idiopathic CD4+ Lymphocytopenia across the complete product development cycle including all clinical and non-clinical stages

It comprises of detailed profiles of Idiopathic CD4+ Lymphocytopenia therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details

Detailed Idiopathic CD4+ Lymphocytopenia Research and Development progress and trial details, results wherever available, are also included in the pipeline study

Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type

Coverage of dormant and discontinued pipeline projects along with the reasons if available across Idiopathic CD4+ Lymphocytopenia

Reasons to Buy

Establish a comprehensive understanding of the current pipeline scenario across Idiopathic CD4+ Lymphocytopenia to formulate effective R&D strategies

Assess challenges and opportunities that influence Idiopathic CD4+ Lymphocytopenia R&D

Develop strategic initiatives by understanding the focus areas of leading companies.

Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

Get in detail information of each product with updated information on each project along with key milestones

Devise Idiopathic CD4+ Lymphocytopenia in licensing and out licensing strategies by identifying prospective partners with progressing projects for Idiopathic CD4+ Lymphocytopenia to enhance and expand business potential and scope

Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

Contents

1. REPORT INTRODUCTION

2. IDIOPATHIC CD4+ LYMPHOCYTOPENIA

- 2.1. Idiopathic CD4+ Lymphocytopenia Disease Overview
- 2.2. Idiopathic CD4+ Lymphocytopenia History
- 2.3. Idiopathic CD4+ Lymphocytopenia Symptoms
- 2.4. Idiopathic CD4+ Lymphocytopenia Causes
- 2.5. Idiopathic CD4+ Lymphocytopenia Pathophysiology
- 2.6. Idiopathic CD4+ Lymphocytopenia Diagnosis
 - 2.6.1. Diagnostic Guidelines

3. IDIOPATHIC CD4+ LYMPHOCYTOPENIA CURRENT TREATMENT PATTERNS

- 3.1. Treatment Guidelines

4. IDIOPATHIC CD4+ LYMPHOCYTOPENIA- DELVEINSIGHT'S ANALYTICAL PERSPECTIVE

- 4.1. In-depth Commercial Assessment
 - 4.1.1. Idiopathic CD4+ Lymphocytopenia companies collaborations, Licensing, Acquisition –Deal Value Trends
 - 4.1.1.1. Assessment Summary
 - 4.1.2. Idiopathic CD4+ Lymphocytopenia Collaboration Deals
 - 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
 - 4.1.2.2. Idiopathic CD4+ Lymphocytopenia Acquisition Analysis
- 4.2. Clinical Assessment of Pipeline Drugs
 - 4.2.1. Assessment by Phase of Development
 - 4.2.2. Assessment by Product Type (Mono / Combination)
 - 4.2.2.1. Assessment by Stage and Product Type
 - 4.2.3. Assessment by Route of Administration
 - 4.2.3.1. Assessment by Stage and Route of Administration
 - 4.2.4. Assessment by Molecule Type
 - 4.2.4.1. Assessment by Stage and Molecule Type
 - 4.2.5. Assessment by MOA
 - 4.2.5.1. Assessment by Stage and MOA

5. IDIOPATHIC CD4+ LYMPHOCYTOPENIA PIPELINE THERAPEUTICS

- 5.1. Late Stage Products (Phase-III)
 - 5.1.1. Comparative Analysis
- 5.2. Mid Stage Products (Phase-II)
 - 5.2.1. Comparative Analysis
- 5.3. Early Stage Products (Phase-I)
 - 5.3.1. Comparative Analysis
- 5.4. Pre-clinical and Discovery Stage Products
 - 5.4.1. Comparative Analysis
- 5.5. Inactive Products

6. IDIOPATHIC CD4+ LYMPHOCYTOPENIA-PRODUCTS ANALYSIS

- 6.1. Product Profiles
 - 6.1.1. Hyleukin-7- NeolImmuneTech
 - 6.1.1.1. Product Description
 - 6.1.1.1.1. Product Overview
 - 6.1.1.1.2. Mechanism of Action
 - 6.1.1.2. Research and Development
 - 6.1.1.2.1. Clinical Studies
 - 6.1.1.2.1.1. Detailed Study Description
 - 6.1.1.2.1.2. Study Results
 - 6.1.1.2.1.3. Clinical Trials: Tabular View
 - 6.1.1.3. Product Development Activities
 - 6.1.1.3.1. Tabulated Product Summary
 - 6.1.1.3.1.1. General Description Table
- To be continued in the report.....

7. RECENT TECHNOLOGIES

8. IDIOPATHIC CD4+ LYMPHOCYTOPENIA KEY COMPANIES

- 8.1. Revimmune SAS
- 8.2. Genexine
- 8.3. NeolImmuneTech

9. IDIOPATHIC CD4+ LYMPHOCYTOPENIA KEY PRODUCTS

- 9.1. Interleukin 7
- 9.2. Efineptakin alfa
- 9.3. Hyleukin-7

10. DORMANT AND DISCONTINUED PRODUCTS

- 10.1. Dormant Products
 - 10.1.1. Reasons for being dormant
- 10.2. Discontinued Products
 - 10.2.1. Reasons for the discontinuation

11. IDIOPATHIC CD4+ LYMPHOCYTOPENIA- UNMET NEEDS

12. IDIOPATHIC CD4+ LYMPHOCYTOPENIA- FUTURE PERSPECTIVES

13. APPENDIX

14. REPORT METHODOLOGY

- 14.1. Secondary Research
- 14.2. Expert Panel Validation

List Of Tables

LIST OF TABLES

- Table 1. Idiopathic CD4+ Lymphocytopenia Diagnostic Guidelines
- Table 2. Treatment Guidelines
- Table 3. Assessment Summary
- Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
- Table 5. Idiopathic CD4+ Lymphocytopenia Acquisition Analysis
- Table 6. Assessment by Phase of Development
- Table 7. Assessment by Product Type (Mono / Combination)
- Table 8. Assessment by Stage and Product Type
- Table 9. Assessment by Route of Administration
- Table 10. Assessment by Stage and Route of Administration
- Table 11. Assessment by Molecule Type
- Table 12. Assessment by Stage and Molecule Type
- Table 13. Assessment by MOA
- Table 14. Assessment by Stage and MOA
- Table 15. Late Stage Products (Phase-III)
- Table 16. Mid Stage Products (Phase-II)
- Table 17. Early Stage Products (Phase-I)
- Table 18. Pre-clinical and Discovery Stage Products
- Table 19. Inactive Products
- Table 20. Dormant Products
- Table 21. Discontinued Products

List Of Figures

LIST OF FIGURES

- Figure 1. Disease Overview
- Figure 2. History
- Figure 3. Symptoms
- Figure 4. Causes
- Figure 5. Pathophysiology
- Figure 6. Diagnostic Guidelines
- Figure 7. Treatment Guidelines
- Figure 8. Idiopathic CD4+ Lymphocytopenia companies collaborations, Licensing, Acquisition –Deal Value Trends
- Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
- Figure 10. Idiopathic CD4+ Lymphocytopenia Acquisition Analysis
- Figure 11. Assessment by Phase of Development
- Figure 12. Assessment by Product Type (Mono / Combination)
- Figure 13. Assessment by Stage and Product Type
- Figure 14. Assessment by Route of Administration
- Figure 15. Assessment by Stage and Route of Administration
- Figure 16. Assessment by Molecule Type
- Figure 17. Assessment by Stage and Molecule Type
- Figure 18. Assessment by MOA
- Figure 19. Assessment by Stage and MOA
- Figure 20. Late Stage Products (Phase-III)
- Figure 21. Mid Stage Products (Phase-II)
- Figure 22. Early Stage Products (Phase-I)
- Figure 23. Pre-clinical and Discovery Stage Products
- Figure 24. Inactive Products
- Figure 25. Dormant Products
- Figure 26. Discontinued Products
- Figure 27. Unmet Needs

KEY COMPANIES

Revimmune SAS
Genexine
Merck & Co
Biogen Idec

Millennium Pharmaceuticals
Ono Pharmaceutical
Chiron
Bayer
Sanofi

I would like to order

Product name: Idiopathic CD4+ Lymphocytopenia - Pipeline Insight, 2019

Product link: <https://marketpublishers.com/r/IABE7B897EEEN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IABE7B897EEEN.html>